Primary Outcome Measures
- Association between PPI consumption and pemetrexed-related hematological toxicity (grade ≥ 3) [ Time Frame: Day 0 ]
The hematological toxicity will be found on biologic data the day or the day before chemotherapy. Classification will based on NCI-CTCAE criteria
Eligibility Criteria
- Inclusion Criteria
- Patients who receive a pemetrexed-based chemotherapy regimen for the treatment of non-small cell lung cancer (NSCLC) or mesothelioma,
- Patients who consent to participate,
- Patients for whom it is possible to characterize the consumption of proton pump inhibitors with name of the PPI
- Patients who consent to participate,
- Exclusion Criteria
- Patients who receive pemetrexed out of intravenous of for another condition than NSCLC or mesothelioma
- Patients under 18 or who refused the participation in the data collection,
- Patient previously treated by a pemetrexed-based chemotherapy,
- Patients who first receive a pemetrexed-based regimen with an initial dose adjustment (<500 mg/m²) and dosage.
- Patients under 18 or who refused the participation in the data collection,